Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 11;14(15):2895-2907.
doi: 10.7150/jca.86568. eCollection 2023.

Expression And Prognostic Role of PRDX1 In Gastrointestinal Cancers

Zhou Zhang  1 , Pengli Zhou  2 , Mingyue Liu  3 , Bing Pei  4
Affiliations

Expression And Prognostic Role of PRDX1 In Gastrointestinal Cancers

Zhou Zhang et al. J Cancer. .

Abstract

Esophageal, gastric, liver, and colorectal cancers represent four prevalent gastrointestinal cancers that pose substantial threats to global health due to their high morbidity and mortality rates. Peroxiredoxin 1 (PRDX1), a significant component of the PRDXs family, primarily functions to counteract the peroxides produced by metabolic activities in the body, thereby maintaining the dynamic equilibrium of peroxides in vivo. Intriguingly, PRDX1 expression correlates strongly with cancer's onset, progression, and prognosis. This study mainly applied bioinformatics methods to analyze PRDX1's expression, diagnosis, and prognosis in gastrointestinal cancers and to summarize current research advancements. Evidence from the bioinformatics database suggested that the high expression of PRDX1 was a prominent characteristic of these four gastrointestinal cancers, with this observation reaching statistical significance. The high expression of PRDX1 in gastrointestinal cancer cells also confirms this result. Notably, the primary alteration in PRDX1 within these cancers is the presence of genetic mutations. PRDX1 demonstrated the highest diagnostic efficacy for colorectal cancer. Nevertheless, elevated PRDX1 levels only significantly diminished the survival time of liver cancer patients, exerting no statistically significant impact on the survival duration of patients afflicted by the other three types of gastrointestinal cancers. Recent research has indicated variability in PRDX1 expression across different cancer types, with high expression being predominantly observed in these four gastrointestinal cancers and, in most instances, unfavorable prognosis. These findings broadly align with the results derived from bioinformatics. This research underscores the high expression of PRDX1 in gastrointestinal cancers, its relevance to the diagnosis and prognosis monitoring of these cancers, and its potential to guide clinical treatment for these cancers.

Keywords: PRDX1; expression; gastrointestinal cancers; prognosis..

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Expression and Mutation of PRDX1 in Pan-Cancer. (A) Expression of PRDX1 in Pan-Cancer. (B) Expression of PRDX1 in Pan-Cancer and Normal Samples. (C) The alteration frequency for each mutation type and (D) mutation site. *P<0.05; “ns” represents no statistical significance.
Figure 2
Figure 2
Identification of DEGs of PRDX1 in gastrointestinal cancers. (A-D) Volcano plots of gastrointestinal cancers. (E-H) Box-plots of PRDX1 in gastrointestinal cancers. ***P<0.001; ****P<0.0001. DEGs, Differentially Expressed Genes.
Figure 3
Figure 3
Relative PRDX1 mRNA expression in gastrointestinal cancers. (A-D) Relative PRDX1 mRNA expression in gastrointestinal cancers cells. **P<0.01; ***P<0.001; ****P<0.0001.
Figure 4
Figure 4
Diagnostic efficacy of PRDX1 in gastrointestinal cancers.
Figure 5
Figure 5
Survival analysis of PRDX1 in gastrointestinal cancers. (A-D) Effect of PRDX1 expression level on gastrointestinal cancers patient survival.
Figure 6
Figure 6
Involvement of PRDX1 in redox cycle mechanism.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. - PubMed
    1. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264–79. - PMC - PubMed
    1. Zheng Y, Li Z, Wang Y, Chen W, Lin Y, Guo J. et al. CircRNA: A new class of targets for gastric cancer drug resistance therapy. Pathol Oncol Res. 2023;29:1611033. - PMC - PubMed
    1. Huang J, Lucero-Prisno DE 3rd, Zhang L, Xu W, Wong SH, Ng SC. et al. Updated epidemiology of gastrointestinal cancers in East Asia. Nat Rev Gastroenterol Hepatol. 2023;20:271–87. - PubMed
    1. Harris IS, DeNicola GM. The Complex Interplay between Antioxidants and ROS in Cancer. Trends Cell Biol. 2020;30:440–51. - PubMed